Partnerships and co-selling vs the traditional approach: what actually beats what for healthcare and life sciences in North America

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in North America. In this market, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed, so the way you install partnerships and co-selling has to be shaped to that reality from day one.

The debate about partnerships and co-selling is often framed as replacement — new model wipes out old. That framing is wrong. The right question is where each approach wins.

Partnerships and co-selling wins on speed of learning, targeting precision, and cost per outcome. It is using another company's distribution to reach buyers you cannot cost-effectively reach yourself, and it compounds in ways the traditional approach cannot match.

The traditional approach wins on relationship depth, brand consistency, and situations where the buyer has already self-identified. Ignoring that is why some teams' first partnerships and co-selling attempt underperforms — they replace the wrong parts.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in North America it is compounded by the fact that signal above noise, not lead volume is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.

Combine them deliberately. Use partnerships and co-selling to find and qualify; use the traditional approach to close and expand. The seam between them is where most pipeline is lost or won.

Metric to watch when running both: sourced and influenced pipeline from partners, plus source attribution. The two approaches should not cannibalise each other; if they do, your handoff is broken.

The failure mode of running both is signing MOUs no one operationalises — usually because the traditional team feels threatened and the new model is starved of context.

Companies that get this right end up with a hybrid engine that outperforms either pure model. Companies that pick one and evangelise it lose to the ones that combine.

Concretely for healthcare and life sciences in North America: the healthcare teams that install this get past procurement instead of dying in it, and the North American teams that install this land inside the first quarter, not the fourth. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.